

Table of Contents

Hyman, Phelps & McNamara, P.C.	v
About the Editors	vii
About the Contributors	ix
Table of Chapters	xxi
Preface	lv

Chapter 1 FDA Administrative Actions

James P. Ellison & Anne K. Walsh

§ 1:1	Overview	1-3
§ 1:2	FDA's Administrative Authority	1-3
§ 1:2.1	Generally	1-3
§ 1:2.2	Jurisdiction Granted to FDA Under the FDC Act	1-4
§ 1:2.3	FDA's Shared Authority with Other Agencies	1-5
[A]	Generally	1-5
[B]	U.S. Department of Health and Human Services	1-5
[B][1]	Centers for Medicare and Medicaid Services	1-6
[C]	U.S. Department of Justice	1-6
[C][1]	Consumer Protection Branch	1-6
[C][2]	U.S. Attorneys	1-7
[C][3]	Drug Enforcement Administration	1-7
[D]	Federal Trade Commission	1-7
[E]	U.S. Department of Agriculture	1-7
[F]	Environmental Protection Agency	1-7
[G]	U.S. Patent and Trademark Office	1-8
[H]	States	1-8
[I]	International MOUs	1-8
§ 1:3	What Triggers an Administrative Action?	1-8
§ 1:3.1	Generally	1-8
§ 1:3.2	Types of FDA Action	1-9
§ 1:3.3	Common Acts Leading to Administrative Actions	1-9
[A]	Label and Labeling Violations	1-9
[B]	Product Adulteration and Quality Issues	1-10
[C]	Acts by Individuals	1-10

§ 1:4	Types of Administrative Actions	1-11
§ 1:4.1	Inspections and Remote Regulatory Assessments	1-11
[A]	Generally	1-11
[B]	Form 483s	1-12
[C]	Examples	1-12
Table 1-1	FDA Form 483 Observations	1-13
§ 1:4.2	Warning and Untitled Letters	1-14
[A]	Generally	1-14
[A][1]	Warning Letters	1-14
[A][2]	Untitled Letters	1-16
[B]	Effect on Future FDA Action.....	1-16
[B][1]	Interactions with FDA.....	1-16
[B][2]	Reputational Harm.....	1-16
[C]	Common Categories.....	1-16
§ 1:4.3	Recalls	1-16
[A]	Generally	1-16
[A][1]	Mandatory Versus Permissive.....	1-16
[B]	Effect on Future Acts	1-18
[B][1]	Interactions with FDA.....	1-18
[B][2]	Reputational Harm.....	1-18
[C]	Examples	1-18
[C][1]	Food	1-18
[C][2]	Drugs: Compounded Drugs	1-18
§ 1:4.4	Import Detentions	1-18
[A]	Generally	1-18
[B]	OASIS System.....	1-19
[C]	Effect on Future FDA Action.....	1-19
[C][1]	Interactions with FDA.....	1-19
[C][2]	Reputational Harm.....	1-19
[D]	Examples	1-19
§ 1:4.5	Administrative Detentions.....	1-20
[A]	Generally	1-20
[A][1]	Food	1-20
[A][2]	Devices.....	1-20
[A][3]	Drugs	1-21
[B]	Effect on Future FDA Action.....	1-21
[C]	Examples	1-21
§ 1:4.6	Clinical Holds.....	1-21
[A]	Generally	1-21
[B]	Effect on Future FDA Action.....	1-22
[C]	Examples	1-22
§ 1:4.7	Application Integrity Policy.....	1-22
[A]	Generally	1-22
[B]	Effect on Future FDA Action.....	1-22

Table of Contents

§ 1:4.8	Civil Monetary Penalties.....	1-23
[A]	Generally	1-23
[B]	Effect on Future Acts	1-23
[C]	Examples	1-23
§ 1:4.9	Disqualification of Clinical Investigators	1-23
[A]	Generally	1-23
[B]	Effect on Future Acts	1-24
[C]	Examples	1-24
§ 1:4.10	Debarment.....	1-24
[A]	Generally	1-24
[A][1]	Individuals Versus Corporate Entities.....	1-24
[A][2]	Mandatory Versus Permissive.....	1-25
[A][3]	Difference from Disqualification	1-25
[B]	Effect on Future Acts	1-25
[B][1]	Temporary Versus Permanent.....	1-25
[B][2]	Potential for Termination	1-25
[C]	Examples	1-26
§ 1:4.11	Publicity.....	1-26
[A]	Generally	1-26
[B]	Effect on Future Acts	1-26
§ 1:5	Frequency of Administrative Actions	1-27
§ 1:5.1	Commonly Used Actions.....	1-27
[A]	Warning and Untitled Letters	1-27
[B]	Recalls	1-27
[C]	Import Detentions	1-27
§ 1:5.2	Less Common Actions.....	1-27
§ 1:6	Facing Administrative Actions.....	1-27
§ 1:6.1	What to Do.....	1-27
§ 1:6.2	What NOT to Do	1-28
§ 1:6.3	Avoiding Administrative Action.....	1-28

Chapter 2 **FDA Civil Enforcement Actions**

Anne K. Walsh, Robert A. Dormer & Kalie E. Richardson

§ 2:1	Overview	2-2
§ 2:2	Relevant Government Actors.....	2-2
§ 2:2.1	FDA Offices	2-2
[A]	Office of Regulatory Affairs	2-2
[B]	Centers' Office of Compliance	2-3
[C]	Office of the Chief Counsel	2-4
§ 2:2.2	U.S. Department of Justice	2-4
[A]	Civil Division, Consumer Protection Branch.....	2-4
[B]	U.S. Attorneys' Offices	2-5

§ 2:3	Guidelines for Taking Enforcement Action	2-6
§ 2:3.1	Regulatory Procedures Manual	2-6
§ 2:3.2	Compliance Policy Guides	2-6
§ 2:3.3	Enforcement Discretion	2-7
§ 2:3.4	DOJ Enforcement Policy	2-9
§ 2:4	Seizures	2-10
§ 2:4.1	Overview	2-10
§ 2:4.2	Legal Authority	2-11
§ 2:4.3	What Products Can Be Seized?	2-12
§ 2:4.4	Procedures	2-14
[A]	Judicial Procedure	2-14
[B]	Coordination with U.S. Marshals Service	2-15
[C]	Disposition of Seized Product	2-15
§ 2:4.5	Challenging a Seizure Action	2-16
§ 2:5	Injunctions	2-17
§ 2:5.1	Overview	2-17
§ 2:5.2	Legal Authority	2-17
[A]	Overview	2-17
[B]	Types of Injunctions	2-18
[B][1]	Temporary Restraining Order	2-18
[B][2]	Preliminary Injunction	2-19
[B][3]	Permanent Injunction	2-19
[C]	Factors Considered by FDA	2-19
§ 2:5.3	Procedures for Initiating an Injunction Action	2-20
[A]	Initial Decision	2-20
[B]	Review by Office of the Chief Counsel	2-21
[C]	Referral to Department of Justice	2-22
§ 2:5.4	Defending Against an Injunction Action	2-22
§ 2:5.5	Consent Decree Provisions	2-22
§ 2:5.6	Vacating an Injunction	2-25
§ 2:6	Equitable Remedies: Restitution and Disgorgement	2-26

Chapter 3 FDA Criminal Enforcement Actions

James P. Ellison

§ 3:1	Overview	3-2
§ 3:2	FDC Act Violations	3-3
§ 3:2.1	Section 301 Prohibited Acts As the Basis for Criminal Violations	3-3
[A]	Generally	3-3
[B]	FDA Regulations As the Basis for a Criminal Charge	3-3
§ 3:2.2	FDC Act Strict Liability Criminal Violations	3-4
[A]	Regulated Persons and Entities	3-4

Table of Contents

[B]	Responsible Corporate Officers	3-4
[B][1]	Generally.....	3-4
[B][2]	Precedent of <i>Dotterweich</i> and <i>Park</i>	3-5
[B][3]	Impossibility Defense.....	3-7
§ 3:2.3	Felony Violations of the FDC Act	3-8
[A]	Generally	3-8
[B]	“Second” Offenses	3-9
[B][1]	Generally.....	3-9
[B][2]	It Is Only a Second Offense If the Government Charges It As Such	3-9
[C]	Intent to Defraud or Mislead FDA or Consumers	3-10
§ 3:2.4	Other Title 21 Criminal Violations.....	3-10
§ 3:2.5	FDC Act Criminal Penalties	3-11
[A]	Terms of Imprisonment.....	3-11
[B]	Fines	3-11
[B][1]	Generally.....	3-11
[B][2]	Alternative Fine Provision of 18 U.S.C. § 3571(d)	3-12
§ 3:2.6	Title 21 Statute of Limitations.....	3-12
§ 3:3	Title 18 Alternatives to FDC Act Charges	3-13
§ 3:3.1	Alternative Criminal Statutes	3-13
[A]	Mail Fraud Act, 18 U.S.C. § 1341.....	3-13
[B]	Wire Fraud Act, 18 U.S.C. § 1343	3-13
[C]	Criminal Conspiracy Statute, 18 U.S.C. § 371	3-13
[D]	Racketeer Influenced and Corrupt Organizations Act, 18 U.S.C. §§ 1961–1968	3-13
[E]	Health Care Fraud, 18 U.S.C. § 1347	3-14
[F]	False Statements, 18 U.S.C. § 1001.....	3-14
[G]	Obstruction of Proceedings Before Agencies, 18 U.S.C. § 1505	3-14
§ 3:3.2	Longer Statutory Maximum Terms of Imprisonment.....	3-14
§ 3:3.3	Simpler Jury Instructions.....	3-15
§ 3:3.4	Statute of Limitations	3-15
§ 3:4	Prosecutors	3-15
§ 3:4.1	U.S. Attorneys	3-15
§ 3:4.2	Consumer Protection Branch.....	3-15
§ 3:4.3	FDA Office of the Chief Counsel	3-16
§ 3:5	Jurisdictional Considerations.....	3-16
§ 3:5.1	Where Can an FDA Case Be Brought?	3-16
§ 3:5.2	Extra-Territorial Application	3-16
§ 3:5.3	Extradition.....	3-16

§ 3:6 Current Trends in Criminal Prosecution:
Qui Tams and Parallel Proceedings 3-17
 § 3:6.1 Generally 3-17
 § 3:7 Sentencing Guidelines 3-17

Chapter 4 Other Authorities Governing FDA-Regulated Entities

*Michelle L. Butler, Larry K. Houck,
 Alan M. Kirschenbaum, Riëtte van Laack,
 Ricardo Carvajal & Faraz R. Siddiqui*

§ 4:1 Overview 4-2
 § 4:2 FTC Regulation of Advertising for FDA-Regulated
 Products 4-3
 § 4:2.1 Generally 4-3
 § 4:2.2 Labeling and Advertising of Over-the-Counter
 Products 4-3
 [A] Substantiation of Advertising Claims 4-3
 [B] FTC Investigative and Enforcement Tools 4-5
 [B][1] Generally 4-5
 [B][2] Enforcement Actions 4-7
 § 4:2.3 “Made in the U.S.A.” 4-10
 § 4:2.4 Overlap with Self-Regulatory Bodies—National
 Advertising Division, Electronic Retailing
 Self-Regulation Program, and Children’s
 Advertising Review Unit 4-13
 § 4:3 Drug Enforcement Administration 4-14
 § 4:4 U.S. Department of Agriculture: Plant and Animal
 Pests, Animal Welfare, and Biotechnology 4-16
 § 4:4.1 Generally 4-16
 § 4:4.2 Imports and Permits 4-16
 § 4:4.3 Animal Welfare 4-17
 § 4:4.4 Biotechnology 4-18
 § 4:5 Agencies Administering Certain Health Care and
 Price Reporting Laws 4-20
 § 4:5.1 Generally 4-20
 § 4:5.2 Health Care Fraud and Abuse Laws 4-20
 § 4:5.3 Government Price Reporting and Government
 Drug Discount Programs 4-21
 [A] Medicaid Drug Rebate Program 4-21
 [B] 340B Drug Discount Program 4-23
 [C] Medicare Part B and Average Sales Price 4-24
 [D] Medicare Part D and the Coverage Gap
 Discount Program 4-25

Table of Contents

[E]	Price Negotiation Under Medicare Parts B and D.....	4-26
[F]	Federal Supply Schedule Contracts	4-28
[G]	TRICARE Retail Refund Program	4-30
§ 4:5.4	Branded Pharmaceutical Fee	4-30
§ 4:6	Customs and Border Protection.....	4-31
§ 4:6.1	Generally	4-31
§ 4:6.2	Import Inspections.....	4-31
§ 4:6.3	Country of Origin Labeling.....	4-32
§ 4:7	State Attorneys General.....	4-34
§ 4:7.1	Generally	4-34
§ 4:7.2	State Food, Drug, and Cosmetic Acts.....	4-34
§ 4:7.3	State Consumer Protection Acts and Unfair Competition Laws	4-35
§ 4:7.4	State False Claims Acts.....	4-36
§ 4:7.5	State Slack-Fill Regulations.....	4-37
§ 4:7.6	California Proposition 65.....	4-38
§ 4:8	International Regulatory Bodies.....	4-38
§ 4:8.1	World Health Organization/Food and Agriculture Organization, Codex Alimentarius Commission—International Food Standards.....	4-39
§ 4:8.2	WHO—Drug Prequalification	4-39
§ 4:9	Product Liability	4-40

Chapter 5 Over-the-Counter Drugs

*Paul M. Hyman, Riëtte van Laack &
Deborah L. Livornese*

§ 5:1	Introduction	5-2
§ 5:2	Definition of Over-the-Counter Drugs	5-3
§ 5:3	OTC Drugs Marketed Under a Monograph.....	5-4
§ 5:3.1	Generally	5-4
§ 5:3.2	OTC Drug Review Process.....	5-5
[A]	Original OTC Drug Review	5-5
[B]	OTC Monograph Reform.....	5-8
[B][1]	Reform of the OTC Monograph Drug Review Process	5-8
[B][1][a]	Revised Status of Drugs Currently Covered by the OTC Drug Review.....	5-8
[B][1][b]	New Administrative Orders	5-9
[B][1][b][i]	Proposed Ordinary Orders Issued on FDA's Initiative	5-9
[B][1][b][ii]	Imminent Hazard Orders and Safety Labeling Changes	5-10

	[B][1][b][iii]	Orders Initiated on Request.....	5-10
	[B][1][c]	Exclusivity.....	5-11
	[B][1][d]	Appeals and Hearings Related to Final Orders	5-11
	[B][1][e]	Minor Changes in Dosage Form.....	5-12
	[B][2]	User Fees; the OTC Monograph User Fee Act.....	5-12
	[B][2][a]	Facility Fees.....	5-12
	[B][2][b]	Order Fees	5-13
	[B][2][c]	Timing/FDA Goals Letter.....	5-13
	[C]	FDA Monograph Orders; Implementation of the CARES Act	5-14
§ 5:3.3		General OTC Drug Labeling Requirements	5-15
§ 5:3.4		Monograph Requirements.....	5-16
	[A]	Generally	5-16
	[B]	Active Ingredients	5-16
	[C]	Indications.....	5-19
	[D]	Dosage Strength and Route of Administration.....	5-19
	[E]	Warnings and Directions	5-19
	[F]	Formulation Testing.....	5-20
	[G]	Claims	5-20
§ 5:4		FDA Enforcement of Monograph Requirements	5-21
	§ 5:4.1	Generally	5-21
	§ 5:4.2	Inspections	5-21
	§ 5:4.3	Warning Letters.....	5-22
	§ 5:4.4	Additional Enforcement Actions	5-23
§ 5:5		Other Paths to Market	5-23
	§ 5:5.1	Generally	5-23
	§ 5:5.2	Direct-to-OTC NDA	5-23
	§ 5:5.3	NDA Deviation.....	5-24
	§ 5:5.4	NDA Supplement	5-25
	§ 5:5.5	505(b)(2) NDA.....	5-25
	§ 5:5.6	ACNU; Another Type of OTC Drug	5-25
	§ 5:5.7	Homeopathic Drugs.....	5-27
	§ 5:5.8	Unapproved Drugs.....	5-29
§ 5:6		Entities Responsible for Enforcement	5-29
	§ 5:6.1	FDA	5-29
	§ 5:6.2	U.S. Department of Justice	5-30
	§ 5:6.3	Federal Trade Commission	5-30
	§ 5:6.4	Others.....	5-31

Chapter 6 Drugs: Current Good Manufacturing Practice

Mark I. Schwartz & Douglas B. Farquhar

§ 6:1	Introduction	6-2
§ 6:2	GMPs Versus cGMPs.....	6-4
§ 6:3	FDA's Risk-Based Approach to Its Statutory Mandate	6-5
§ 6:4	Scope of cGMPs.....	6-6
§ 6:4.1	Introduction.....	6-6
§ 6:4.2	Drug Substance Versus Drug Product	6-6
§ 6:4.3	Investigational Drug Products.....	6-7
§ 6:4.4	Excipients	6-9
§ 6:4.5	For Export Only	6-9
§ 6:5	General Principles of cGMPs	6-10
§ 6:5.1	Introduction.....	6-10
§ 6:5.2	Quality Management System—The Foundation for Compliance	6-10
[A]	Introduction	6-10
[B]	Management Oversight and Review.....	6-11
[C]	The Quality Unit.....	6-12
[D]	Quality System Development and Implementation.....	6-13
[E]	Training and Education.....	6-14
[F]	Quality Metrics.....	6-15
§ 6:5.3	Control Over Process	6-17
[A]	Generally	6-17
[B]	Process Understanding	6-17
[C]	In-Process Controls	6-18
[D]	Process Validation.....	6-18
§ 6:5.4	Control Over Materials.....	6-19
[A]	Generally.....	6-19
[B]	Vendor Controls.....	6-20
[C]	Raw Materials.....	6-21
[D]	Manufacturing Equipment.....	6-21
[E]	Packaging.....	6-21
[E][1]	Generally.....	6-21
[E][2]	Container and Closure Systems	6-22
[E][3]	Outer Packaging and Labeling	6-22
§ 6:5.5	Control Over Product.....	6-23
[A]	Generally	6-23
[B]	Laboratory Testing and Product Release	6-23
[C]	Shipment and Distribution.....	6-23
[D]	Stability Testing	6-24
§ 6:5.6	Control Over Records	6-24
[A]	Generally	6-24

	[B]	Recordkeeping.....	6-24
	[C]	Record Retention	6-25
	[D]	Data Integrity	6-25
§ 6:5.7		Control Over the Unexpected	6-27
	[A]	Generally	6-27
	[B]	Deviations	6-27
	[C]	Out of Specification Results.....	6-27
	[D]	Complaints.....	6-28
	[E]	Investigations	6-28
	[F]	Corrective and Preventive Actions	6-28
§ 6:6		Putting the “c” in cGMPs	6-29
§ 6:6.1		Introduction.....	6-29
§ 6:6.2		Routine Internal Auditing.....	6-29
§ 6:6.3		Review of Procedures and Protocols	6-30
§ 6:6.4		Maintaining Industry Awareness	6-30
	[A]	Generally	6-30
	[B]	Sources of Best Practices	6-30
	[B][1]	FDA Inspections and Warning Letters	6-30
	[B][2]	FDA Guidance	6-30
	[B][3]	USP and Other Compendia.....	6-30
	[B][4]	ICH.....	6-31
	[C]	Keeping Up with Technology	6-31
§ 6:7		Enforcement and Penalties	6-31
§ 6:7.1		Pre-Approval and Routine Facility Inspections	6-31
§ 6:7.2		Impact on Pending or Future Submissions.....	6-32
§ 6:7.3		Enforcement Trends.....	6-33

Chapter 7 Drug Compounding

Karla L. Palmer

§ 7:1		Pharmaceutical Compounding: Well-Recognized and Critically Important.....	7-2
§ 7:2		Food and Drug Administration Modernization Act and Its Tortured Constitutional History: Federal Courts Divide Over Compounding.....	7-3
§ 7:3		New England Compounding Center and 2013 Congressional Action.....	7-5
§ 7:4		Passage of the Drug Quality and Security Act, Title I (the Compounding Quality Act)	7-9
§ 7:4.1		Generally	7-9
§ 7:4.2		Reinstated Section 503A; Reinvigorated FDA	7-10
	[A]	Generally	7-10
	[B]	FDA’s Guidance Addressing Section 503A.....	7-14

Table of Contents

[C]	FDA's Final Memorandum of Understanding with States on Interstate Shipments of Compounded Products	7-18
§ 7:4.3	Section 503B: Outsourcing Facilities.....	7-22
[A]	Generally	7-22
[B]	General Section 503B Requirements: Registration, Reporting, cGMP, and FDA Inspections	7-23
[C]	Restrictions on Outsourcing Facility Compounding.....	7-27
[C][1]	Generally.....	7-27
[C][2]	Compounding of Products on FDA's Published Shortage List	7-27
[C][3]	FDA's Section 503B List 1	7-28
[C][4]	Withdrawn Drugs, the Negative List, and "Essentially Copies"	7-31
[C][5]	Prohibition on Wholesaling and Transfers.....	7-34
[C][6]	FDA's "Facility" Definition for Section 503B Outsourcing Facilities.....	7-34
§ 7:4.4	FDA's Pharmacy Compounding Advisory Committee	7-35
[A]	Generally	7-35
[B]	Committee Membership.....	7-35
§ 7:5	Conclusion	7-36

Chapter 8 Clinical Trials

David B. Clissold & James E. Valentine

§ 8:1	Federal Regulation of Clinical Trials	8-3
§ 8:1.1	History and Overview	8-3
§ 8:1.2	U.S. Department of Health and Human Services: Policy for Protection of Human Research Subjects (the "Common Rule")	8-4
§ 8:1.3	FDA Regulations Regarding the Protection of Human Research Subjects.....	8-5
§ 8:2	FDA Regulations for Clinical Studies of Investigational Drugs and Devices.....	8-6
§ 8:2.1	Regulated Entities	8-6
§ 8:2.2	Sponsors	8-7
[A]	General Responsibilities	8-7
[B]	Requirements for an Investigational New Drug Application or Investigational Device Exemption.....	8-8
[B][1]	INDs	8-8
[B][2]	IDEs	8-10

[C]	Selecting Investigators and Monitors	8-13
[D]	Obtaining Information from Investigators	8-14
[D][1]	Generally	8-14
[D][2]	Selecting Monitors	8-16
[D][3]	Informing Investigators	8-17
[E]	Review of Ongoing Clinical Investigations.....	8-18
[F]	Recordkeeping and Retention.....	8-20
[G]	Disposition of Unused Investigational Products.....	8-20
[H]	CROs.....	8-21
§ 8:2.3	Investigators	8-21
[A]	General Responsibilities	8-21
[B]	Control of Investigational Products	8-22
[C]	Recordkeeping and Retention.....	8-22
[D]	Investigator Reporting Requirements	8-22
[E]	Obtaining Informed Consent.....	8-24
[E][1]	Generally	8-24
[E][2]	Required Elements of Informed Consent	8-25
[E][3]	Additional Elements	8-30
[F]	Assurance of IRB Review	8-32
§ 8:2.4	Institutional Review Boards	8-33
[A]	Scope	8-33
[B]	Organization.....	8-34
[C]	Functions and Operations.....	8-35
[D]	Additional Protections: Vulnerable Populations.....	8-38
§ 8:2.5	Clinical Holds and Staged Approval.....	8-42
[A]	Generally	8-42
[B]	Grounds for Imposition of Clinical Hold	8-43
[C]	Process for Imposition of Clinical Hold	8-45
[D]	Resumption of Clinical Investigations	8-46
§ 8:2.6	IND/IDE Termination.....	8-46
§ 8:2.7	IND/IDE Withdrawal.....	8-47
§ 8:3	Clinical Trial Registration and Results Submission.....	8-47
§ 8:3.1	Regulatory History	8-47
§ 8:3.2	Applicable Clinical Trials	8-49
§ 8:3.3	Responsible Party	8-50
§ 8:3.4	Registration.....	8-51
§ 8:3.5	Results Reporting of Completed Trials	8-52
§ 8:3.6	ClinicalTrials.gov Compliance	8-55
§ 8:4	Potential Conflicts of Interest and Financial Disclosure Regulations	8-56
§ 8:5	Postmarketing Studies	8-60

Table of Contents

§ 8:5.1 Postmarketing Commitments and Requirements for Drugs 8-60

§ 8:5.2 Post-Approval Studies for Devices 8-61

§ 8:5.3 Confirmatory Studies for Accelerated Drug Approvals 8-63

§ 8:5.4 Postmarketing Requirements for Drugs Approved Under the Animal Rule 8-64

§ 8:5.5 Pediatric Postmarketing Studies 8-65

§ 8:6 FDA Inspections and Enforcement Mechanisms 8-65

§ 8:6.1 Bioresearch Monitoring Program 8-65

[A] FDA Inspections of Sponsors and CROs 8-66

[B] FDA Inspections of Clinical Investigators 8-67

[C] FDA Inspections of Institutional Review Boards 8-68

[D] Upon Conclusion of an FDA Inspection 8-69

§ 8:6.2 FDA Enforcement Under BIMO 8-69

[A] Issuing Untitled, Warning, and Restrictions Letters 8-70

[B] Investigator Disqualification 8-70

[C] Debarment 8-73

§ 8:6.3 FDA Inspections and Enforcement 8-73

[A] Clinical Investigators 8-73

[B] Sponsors and CROs 8-74

[C] IRBs 8-74

Appendix 8A Statement of Investigator, Form FDA 1572 App. 8A-1

Chapter 9 Quality System Regulation

Jeffrey K. Shapiro & Allyson B. Mullen

§ 9:1 Overview 9-2

§ 9:2 General Provisions 9-3

§ 9:2.1 Overview 9-3

§ 9:2.2 Scope 9-3

[A] History and Authority 9-3

[B] Applicability 9-4

[B][1] Generally 9-4

[B][2] Foreign Manufacturers 9-5

[C] Exemptions 9-5

§ 9:2.3 Definitions 9-6

§ 9:3 Quality System Requirement 9-7

§ 9:3.1 Generally 9-7

§ 9:3.2 Quality System 9-7

§ 9:3.3 Management Responsibility 9-8

[A] Management with Executive Responsibility 9-8

[B]	Quality Policy	9-8
[C]	Organization and Resources.....	9-9
[C][1]	Generally.....	9-9
[C][2]	Organization	9-9
[C][3]	Resources	9-9
[D]	Responsibility and Authority	9-10
[E]	Management Representative.....	9-10
[F]	Management Review.....	9-11
[G]	Quality Planning.....	9-12
[H]	Quality System Procedures	9-12
§ 9:3.4	Quality Audits	9-13
§ 9:3.5	Personnel	9-14
[A]	Generally	9-14
[B]	Training.....	9-14
§ 9:4	Design Controls	9-15
§ 9:4.1	Design Control Requirements.....	9-15
[A]	Generally	9-15
[B]	Applicability	9-15
[C]	Design and Development Planning.....	9-16
[D]	Design Inputs and Outputs	9-16
[E]	Design Review	9-17
[F]	Design Verification	9-18
[G]	Design Validation.....	9-18
[H]	Design Transfer.....	9-19
[I]	Design Changes.....	9-19
[J]	Design History File, Device Master Record, and Device History Record	9-19
§ 9:5	Purchasing Controls	9-20
§ 9:6	Production and Process Controls	9-21
§ 9:6.1	Production and Process Control Requirements	9-21
§ 9:6.2	Inspection, Measuring, and Test Equipment	9-22
§ 9:6.3	Process Validation	9-22
§ 9:7	Control of Devices.....	9-23
§ 9:7.1	Receiving, In-Process, and Finished Device Acceptance.....	9-23
§ 9:7.2	Acceptance Status and Identification	9-24
§ 9:7.3	Nonconforming Product	9-24
§ 9:8	Corrective and Preventive Action.....	9-25
§ 9:9	Labeling and Traceability	9-26
§ 9:9.1	Labeling Control	9-26
§ 9:9.2	Traceability	9-26
§ 9:10	Records.....	9-27
§ 9:10.1	General Requirements	9-27
§ 9:10.2	Document Controls and Good Documentation Practices.....	9-27

Table of Contents

§ 9:11 Complaint Handling..... 9-28
§ 9:12 Servicing..... 9-29

Chapter 10 Devices: Recalls

Jeffrey K. Shapiro & Allyson B. Mullen

§ 10:1 Overview 10-2
§ 10:2 General Provisions..... 10-2
 § 10:2.1 Scope 10-2
 § 10:2.2 Definitions..... 10-3
 [A] Correction 10-3
 [B] Removal..... 10-3
 [C] Market Withdrawal..... 10-3
 [D] Risk to Health 10-3
 [E] Routine Servicing..... 10-4
 [F] Stock Recovery..... 10-4
 § 10:2.3 Types of Recalls..... 10-4
 [A] Firm-Initiated Recall..... 10-4
 [B] FDA-Requested Recall..... 10-5
 [C] FDA Mandatory Recall Authority 10-6
§ 10:3 Identification and Classification 10-7
 § 10:3.1 Identifying Potential Recalls..... 10-7
 § 10:3.2 Health Risk Assessment/Health Hazard
 Evaluation..... 10-7
 § 10:3.3 Classification 10-8
§ 10:4 Recall Execution 10-8
 § 10:4.1 Strategy..... 10-8
 [A] Generally 10-8
 [B] Elements of a Recall Strategy 10-9
 [B][1] Depth of Recall..... 10-9
 [B][2] Public Warning 10-9
 [B][3] Effectiveness Checks 10-9
 § 10:4.2 Communication 10-9
 [A] Consignee Communication 10-9
 [B] Public Notification..... 10-10
 § 10:4.3 Recall Status Reports 10-10
 § 10:4.4 Termination..... 10-11
§ 10:5 Reporting to FDA..... 10-12
 § 10:5.1 Scope 10-12
 [A] Applicability 10-12
 [B] Exemptions..... 10-13
 § 10:5.2 Initial Reports 10-14
 § 10:5.3 Status Reports..... 10-16
§ 10:6 Recordkeeping..... 10-16

§ 10:6.1 Recall Records 10-16
 § 10:6.2 Access to Recall Records 10-17
 Appendix 10A Form Template HHE App. 10A-1
 Appendix 10B Recall Notification Letter App. 10B-1

Chapter 11 Devices: Medical Device Reports

Jeffrey K. Shapiro & Allyson B. Mullen

§ 11:1 Overview 11-2
 § 11:2 General Provisions 11-2
 § 11:2.1 Scope 11-2
 [A] Authority 11-2
 [B] Applicability of MDR Requirements to
 Regulated Industries 11-3
 [B][1] Manufacturer 11-3
 [B][2] Importer 11-4
 [B][3] User Facility 11-4
 [C] Exemptions, Variances, and Alternative
 Reporting 11-5
 § 11:2.2 General Provisions 11-6
 [A] Public Disclosure of MDRs 11-6
 [B] MDRs Not an Admission 11-6
 § 11:3 Reportable Events 11-7
 § 11:3.1 Death or Serious Injury 11-8
 § 11:3.2 Malfunction 11-9
 § 11:3.3 Foreign Events 11-11
 § 11:4 Procedures and Record 11-12
 § 11:4.1 MDR Procedure Requirements 11-12
 [A] General Requirements 11-12
 [B] Identification of Reportable Events 11-13
 [B][1] Device-Related Complaint Review 11-13
 [B][2] Receipt of Voluntary Reports 11-13
 § 11:4.2 MDR Files 11-13
 § 11:5 Reporting 11-14
 § 11:5.1 How to Report 11-14
 § 11:5.2 MDR Required Information 11-16
 [A] General Requirements 11-16
 [B] Reporting Codes 11-16
 [C] Multiple Devices 11-17
 § 11:6 Manufacturer Requirements 11-17
 § 11:6.1 Reporting Requirements 11-17
 [A] Thirty-Day Reports 11-17

Table of Contents

[B]	Five-Day Reports	11-17
§ 11:6.2	Supplemental Reports	11-18
§ 11:6.3	Foreign Manufacturers	11-18
§ 11:6.4	Voluntary Malfunction Summary Reporting Program	11-18
§ 11:7	Importer Requirements	11-19
§ 11:8	User Facility Requirements	11-19
§ 11:8.1	Individual Reports	11-19
§ 11:8.2	Annual Reports	11-20
§ 11:9	Distributor Requirements	11-20

Chapter 12 Devices: *In Vitro* Diagnostic Devices

Jeffrey N. Gibbs, Allyson B. Mullen & Gail H. Javitt

§ 12:1	Overview	12-2
§ 12:2	Definition of <i>In Vitro</i> Diagnostics (IVDs)	12-3
§ 12:2.1	Statutory Definition: FDC Act § 201(h)	12-3
§ 12:2.2	Regulation: 21 C.F.R. § 809.3	12-3
§ 12:2.3	Courts Broadly Interpret “Diagnose”	12-3
§ 12:3	Overlap with Other Device Regulatory Provisions	12-6
§ 12:3.1	Office of <i>In Vitro</i> Diagnostics	12-6
§ 12:3.2	Classification Scheme	12-6
§ 12:3.3	Importance of Intended Use	12-7
§ 12:3.4	Premarket Review	12-8
§ 12:3.5	Quality System Regulation	12-9
§ 12:3.6	Recalls, Corrections, and Removals	12-9
§ 12:3.7	Registration and Listing	12-10
§ 12:3.8	Medical Device Reporting	12-10
§ 12:3.9	Labeling/Promotion	12-11
§ 12:4	Laboratory-Developed Tests	12-11
§ 12:4.1	Generally	12-11
§ 12:4.2	Clinical Laboratory Improvement Amendments of 1988	12-12
§ 12:4.3	FDA Asserts Authority Over LDTs	12-12
§ 12:4.4	1997 Analyte Specific Reagents Regulation	12-12
§ 12:4.5	Warning Letters	12-14
§ 12:4.6	Active FDA Risk-Based Approach Regulation of LDTs	12-17
§ 12:4.7	“It Has Come to Our Attention” Letters	12-18
§ 12:4.8	FDA Draft Guidance on the Active Regulation of LDTs	12-21
§ 12:4.9	LDT Draft Guidances: Support and Opposition	12-22
§ 12:5	Analyte Specific Reagents	12-25

§ 12:5.1	Definition	12-25
§ 12:5.2	ASR Distribution Limitations	12-26
§ 12:5.3	September 2007 FDA Guidance Narrows Scope of ASRs	12-26
§ 12:6	Research Use Only/Investigational Use Only Products.....	12-27
§ 12:6.1	Research Use Only Products	12-27
§ 12:6.2	Investigational Use Only Products.....	12-30
§ 12:7	Forensic Use	12-31
§ 12:7.1	For Law Enforcement Purposes	12-31
§ 12:7.2	Warning Letters.....	12-33
§ 12:8	General Purpose Reagents	12-35
§ 12:9	SARS-CoV-2 Testing.....	12-36

Chapter 13 Human Food and Dietary Supplements

Riëtte van Laack & Ricardo Carvajal

§ 13:1	Overview	13-3
§ 13:2	Foods	13-4
§ 13:2.1	Generally	13-4
§ 13:2.2	Dietary Supplements	13-4
§ 13:2.3	Meat, Poultry, and Egg Products.....	13-5
§ 13:3	Food and Drug Administration.....	13-8
§ 13:3.1	Generally	13-8
§ 13:3.2	Adulteration.....	13-9
[A]	Generally	13-9
[B]	Unintended Components/Contaminants.....	13-9
[B][1]	Poisonous or Deleterious Substances.....	13-9
[B][2]	Current Good Manufacturing Practice and Hazard Analysis and Critical Control Points.....	13-11
[B][2][a]	Generally.....	13-11
[B][2][b]	Low-Acid Canned Foods and Acidified Foods cGMPs	13-12
[B][2][c]	Infant Formula cGMPs.....	13-13
[B][2][d]	Hazard Analysis and Critical Control Points for Juices, and for Fish and Fishery Products.....	13-14
[B][2][e]	Dietary Supplement cGMPs.....	13-15
[B][3]	Food Safety Modernization Act.....	13-16
[C]	Substances Intentionally Added to Food	13-19
[C][1]	Generally.....	13-19
[C][2]	Food Additives.....	13-20
[C][2][a]	Generally.....	13-20
[C][2][b]	Food Contact Substances	13-20

Table of Contents

[C][3]	Color Additives	13-21
[C][4]	GRAS Uses of Substances	13-22
[C][5]	Pesticides.....	13-23
[C][6]	Dietary Ingredients.....	13-23
§ 13:3.3	Misbranding	13-24
[A]	Generally	13-24
[B]	Mandatory Label Requirements	13-25
[C]	Health Claims	13-28
[D]	Nutrient Content Claims	13-29
[E]	Structure/Function Claims.....	13-30
[F]	Menu Labeling.....	13-31
[G]	Other Labeling Claims.....	13-31
§ 13:3.4	Miscellaneous Provisions.....	13-32
[A]	Facility Registration	13-32
[B]	Distribution and Recordkeeping.....	13-32
[C]	Reportable Food Registry.....	13-33
[D]	Adverse Event Reporting.....	13-33
§ 13:4	FDA Enforcement Powers Related to Foods	13-34
§ 13:4.1	Inspections	13-34
§ 13:4.2	Recalls	13-36
[A]	“Voluntary” Recalls.....	13-36
[B]	Mandatory Recalls	13-37
§ 13:4.3	Warning and Other Letters.....	13-38
[A]	Warning Letters	13-38
[B]	Cyber Letters	13-39
[C]	Courtesy Letters	13-39
§ 13:4.4	Suspension of Facility Registration.....	13-39
§ 13:4.5	Administrative Detention	13-40
§ 13:4.6	Seizure	13-41
§ 13:4.7	Injunction.....	13-42
§ 13:4.8	Criminal Actions	13-42
[A]	Strict Liability	13-42
[B]	Felonies	13-44
§ 13:4.9	Regulatory Compliance Guaranties.....	13-45
§ 13:4.10	Enforcement Actions Related to Import of Foods.....	13-46
[A]	Administrative Holds, Detentions, and Refusals.....	13-46
[B]	Debarment	13-48
§ 13:5	Food Safety and Inspection Service	13-48
§ 13:5.1	Generally	13-48
§ 13:5.2	Adulteration.....	13-50
[A]	Generally	13-50
[B]	HACCP	13-50

[C]	Sanitary, Processing and Facility Requirements for Egg Products Processing.....	13-53
[D]	Ingredients.....	13-53
§ 13:5.3	Misbranding	13-54
§ 13:6	FSIS Enforcement	13-56
§ 13:6.1	Generally	13-56
§ 13:6.2	Inspection-Related Enforcement Powers of FSIS	13-57
§ 13:6.3	Actions Against Products	13-57
[A]	Generally	13-57
[B]	Product Recalls	13-58
§ 13:6.4	Administrative Actions	13-58
[A]	Rules of Practice.....	13-58
[B]	Regulatory Control Actions.....	13-59
[C]	Suspension of Inspection	13-59
[D]	Withholding Action	13-59
[E]	Notices of Intended Enforcement Action	13-60
[F]	Appeals	13-60
[G]	Withdrawal of Inspection.....	13-60
§ 13:6.5	Civil and Criminal Actions.....	13-61
§ 13:6.6	Notice of Warning.....	13-61
§ 13:6.7	Imports	13-61
§ 13:7	Other Federal Agencies Regulating Food	13-62
§ 13:7.1	Generally	13-62
§ 13:7.2	Alcohol and Tobacco Tax and Trade Bureau	13-62
§ 13:8	States.....	13-64
§ 13:8.1	Food Other Than Meat and Poultry	13-64
[A]	Generally	13-64
[B]	Federal-State Cooperative Programs.....	13-65
§ 13:8.2	Meat and Poultry	13-67
§ 13:9	Private Actions	13-67

Chapter 14 Tobacco Products

David B. Clissold, Faraz R. Siddiqui & Sara W. Koblitz

§ 14:1	Overview	14-2
§ 14:2	Scope of Authority	14-2
§ 14:3	Prohibited Adulteration and Misbranding.....	14-4
§ 14:4	Tobacco Product Scientific Advisory Committee.....	14-6
§ 14:5	Establishment of Tobacco Product Standards.....	14-7
§ 14:6	Premarket Authorities for New Tobacco Products	14-9
§ 14:6.1	Generally	14-9
§ 14:6.2	Premarket Notifications.....	14-10
§ 14:6.3	Premarket Applications.....	14-12

Table of Contents

[A]	Generally	14-12
[B]	PMTA Marketing Orders and Denials	14-12
[C]	Withdrawal and Suspension of an Authorized Product	14-15
§ 14:7	Modified Risk Tobacco Products	14-16
§ 14:8	Reporting Requirements	14-17
§ 14:8.1	Registration and Listing	14-17
§ 14:8.2	Health Information and Health Effects	14-17
§ 14:8.3	“Track-and-Trace” Requirements.....	14-19
§ 14:9	Restrictions on the Sale, Distribution, Advertising, and Promotion of Tobacco Products	14-19
§ 14:10	Final Deeming Rule	14-24
§ 14:11	Other Challenges to the Tobacco Control Act and Deeming Rule	14-27
§ 14:12	Enforcement	14-30
§ 14:12.1	State and Federal-State Enforcement Efforts.....	14-30
§ 14:12.2	State Enforcement Efforts: Electronic Cigarettes	14-33
§ 14:12.3	FDA Enforcement Efforts.....	14-34
§ 14:12.4	Warning Letters.....	14-35
§ 14:12.5	Civil Money Penalty Actions.....	14-36
§ 14:12.6	No-Tobacco-Sales Order.....	14-37

Chapter 15 Animal Products

*Karla L. Palmer, David B. Clissold, Riëtte van Laack &
Ricardo Carvajal*

§ 15:1	Overview	15-2
§ 15:2	Authority and Organization.....	15-3
§ 15:3	New Animal Drugs.....	15-4
§ 15:3.1	Premarket Authorities.....	15-4
§ 15:3.2	Investigational Use	15-5
§ 15:3.3	Product Review and Approval.....	15-6
§ 15:3.4	Post-Market Authorities.....	15-7
[A]	Generally	15-7
[B]	Reporting Requirements	15-7
[C]	Changes to an Application.....	15-8
[D]	Withdrawal.....	15-9
§ 15:3.5	Medicated Animal Feed	15-9
§ 15:4	Animal Food and Animal Feed	15-10
§ 15:4.1	Generally	15-10
§ 15:4.2	Premarket Authorities.....	15-12
§ 15:4.3	Food Additive Petitions	15-12
§ 15:4.4	GRAS Ingredients	15-13

§ 15:4.5	AAFCO Feed Ingredient Definitions	15-14
§ 15:5	Animal Supplements	15-15
§ 15:5.1	Regulatory Framework	15-15
§ 15:5.2	National Animal Supplement Council.....	15-16
§ 15:6	Other Product Types	15-17
§ 15:6.1	Veterinary Devices	15-17
§ 15:6.2	Veterinary Biologics	15-18
§ 15:6.3	Pesticides	15-20
§ 15:6.4	Combination Products.....	15-20
§ 15:6.5	Genetically Engineered Animals	15-21
§ 15:6.6	Animal Stem-Cell-Based Products	15-23
§ 15:7	Animal Drug Compounding.....	15-23
§ 15:7.1	Generally	15-23
§ 15:8	Other Use Outside the Scope of an Approval.....	15-26
§ 15:8.1	Generally	15-26
§ 15:8.2	Off-Label and Extra-Label Use	15-28
§ 15:8.3	Indexing and Conditional Approval	15-28
§ 15:8.4	Regulatory Enforcement Discretion	15-31
§ 15:9	Coordination with Other Government Actors	15-31
§ 15:9.1	Other FDA Centers.....	15-31
§ 15:9.2	U.S. Department of Agriculture—Center for Veterinary Biologics	15-32
§ 15:9.3	EPA.....	15-32
§ 15:9.4	State Regulators	15-32
§ 15:10	Enforcement	15-33
§ 15:10.1	Generally	15-33
§ 15:10.2	Court Action.....	15-33
§ 15:10.3	Warning Letters.....	15-34

Chapter 16 Cosmetics

Ricardo Carvajal & Riëtte van Laack

§ 16:1	Overview	16-2
§ 16:2	Definition of “Cosmetic”	16-3
§ 16:3	Statutory and Regulatory Framework.....	16-4
§ 16:4	Adulteration	16-4
§ 16:4.1	Adulteration and Cosmetic Ingredients.....	16-5
[A]	FDA Regulation of Cosmetic Ingredients.....	16-5
[B]	Industry Self-Regulation of Cosmetic Ingredients.....	16-6
§ 16:4.2	Color Additives	16-7
[A]	Color Additives Generally.....	16-7
[B]	The Delaney Clause	16-8
[C]	Coal-Tar Hair Dye Exemption.....	16-9
[D]	Tattoos.....	16-9

Table of Contents

§ 16:4.3	Adulteration and Cosmetic Manufacturing.....	16-10
[A]	Cosmetic GMP Guidance Documents.....	16-11
[B]	Voluntary Cosmetic Registration Program	16-11
§ 16:5	Misbranding	16-12
§ 16:5.1	Mandatory Label Statements	16-14
[A]	Label Versus Labeling.....	16-14
[B]	Requirements Under the Fair Packaging and Labeling Act.....	16-15
[C]	Warnings.....	16-16
§ 16:5.2	Claims	16-17
[A]	Cosmetic Claims Versus Drug Claims.....	16-17
[B]	Other Claims.....	16-19
[C]	Claim Substantiation.....	16-20
§ 16:6	FDA Enforcement of Cosmetic Requirements	16-21
§ 16:6.1	Inspections	16-21
§ 16:6.2	Warning Letters.....	16-21
§ 16:6.3	Additional Enforcement Actions	16-22
§ 16:7	Other Sources of Legal and Regulatory Challenges	16-23
§ 16:8	State Laws Affecting Cosmetics	16-23

Chapter 17 Controlled Substances

John A. Gilbert, Jr. & Larry K. Houck

§ 17:1	Overview	17-2
§ 17:2	Scope of Enforcement	17-4
§ 17:2.1	Classification of Controlled Substances	17-4
§ 17:2.2	Facility and Practitioner Registration	17-5
§ 17:2.3	Security for Storage and Handling.....	17-6
§ 17:2.4	Complete and Accurate Records.....	17-7
§ 17:2.5	Form, Manner, and Content of Prescriptions	17-8
§ 17:2.6	Transaction and Ad Hoc Reporting	17-9
§ 17:3	Type of Enforcement	17-11
§ 17:3.1	Administrative Enforcement Actions	17-11
[A]	Verbal Warning	17-12
[B]	Corrective Letter	17-12
[C]	Voluntary Surrender.....	17-12
[D]	Informal Administrative Hearing.....	17-13
[E]	Order to Show Cause (OTSC).....	17-13
[F]	Immediate Suspension.....	17-15
[G]	Injunction.....	17-16
§ 17:3.2	Civil Penalties.....	17-17
§ 17:3.3	Criminal and Forfeiture Enforcement Actions	17-19
§ 17:4	Examples of Enforcement Cases	17-20
§ 17:4.1	Administrative Revocation and Other Actions Against Practitioners.....	17-20

§ 17:4.2	Administrative and Civil Penalties for Failure to Maintain Complete and Accurate Records.....	17-22
§ 17:4.3	Dispensing for Non-Legitimate Purpose	17-26
§ 17:4.4	Failure to Report Suspicious Orders	17-32
§ 17:4.5	National Prescription Opioid Litigation	17-39
§ 17:4.6	State Prescription Opioid Litigation	17-40
§ 17:4.7	Cases Involving List I Chemicals	17-42
§ 17:4.8	Enforcement Action Against Non-Registrants.....	17-43
§ 17:5	Conclusion	17-45

Chapter 18 Promotion and Marketing of Prescription Drugs, Biologics, and Devices

Dara Katcher Levy, Jeffrey N. Wasserstein & Sara W. Koblitz

§ 18:1	Overview	18-2
§ 18:2	Legal Overview	18-3
§ 18:2.1	Prohibited Acts	18-3
[A]	Generally	18-3
[B]	Misbranding	18-4
[C]	Unapproved New Drug.....	18-4
§ 18:2.2	Classes of Promotional Materials.....	18-5
[A]	Generally	18-5
[B]	Promotional Labeling.....	18-5
[C]	Advertising	18-6
§ 18:3	Promotional Requirements	18-7
§ 18:3.1	Generally	18-7
§ 18:3.2	Substantiation of Claims	18-7
[A]	Generally	18-7
[B]	Comparative Claims.....	18-9
[C]	Implied Claims	18-10
[D]	Pharmacoeconomic Claims	18-11
§ 18:3.3	Fair Balance and Contextualizing Information.....	18-12
§ 18:3.4	Submission of Promotional Materials	18-13
§ 18:4	Types of Promotion.....	18-14
§ 18:4.1	Pre-Approval Promotion.....	18-14
§ 18:4.2	Post-Approval Promotion.....	18-15
[A]	Generally	18-15
[B]	Advertising to Consumers—Specific Requirements.....	18-17
[C]	Reminder Materials	18-19
§ 18:4.3	Excluded Types of Communications	18-20
[A]	Generally	18-20
[B]	Continuing Medical Education (CME) Programs.....	18-20

Table of Contents

[C]	Scientific Exchange	18-20
[D]	Disease Awareness Communications	18-24
§ 18:5	Internet and Social Media.....	18-26
§ 18:5.1	Generally	18-26
§ 18:5.2	Postmarketing Submission of Promotional Materials.....	18-27
§ 18:5.3	Character and Space Limitations	18-27
§ 18:5.4	Correcting Third-Party Misinformation.....	18-27
§ 18:5.5	Additional Issues Related to Internet and Social Media	18-28
§ 18:6	Devices	18-29
§ 18:6.1	Generally	18-29
§ 18:6.2	Device Labeling.....	18-30
§ 18:6.3	Device Advertising.....	18-31
§ 18:6.4	Device Substantiation.....	18-32
§ 18:6.5	Unapproved Device Promotion	18-33
§ 18:6.6	Applicable FDA Guidance Documents.....	18-34
Appendix 18A	FDA Organizations and Areas of Responsibilities	App. 18A-1

Chapter 19 Health Care Fraud and Abuse Laws

Alan M. Kirschenbaum & Sophia R. Gaulkin

§ 19:1	Overview	19-3
§ 19:2	Federal Health Care Program Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b))	19-4
§ 19:2.1	Prohibited Conduct.....	19-4
§ 19:2.2	Statutory Exemptions	19-7
§ 19:2.3	AKS Safe Harbor Regulations.....	19-8
[A]	General Considerations	19-8
[B]	Discounts (42 C.F.R. § 1001.952(h)).....	19-9
[C]	Personal Services and Management Contracts (42 C.F.R. § 1001.952(d)).....	19-14
[D]	Group Purchasing Organizations (42 C.F.R. § 1001.952(j)).....	19-15
[E]	Employees (42 C.F.R. § 1001.952(i))	19-16
[F]	Price Reductions to Eligible Managed Care Organizations (42 C.F.R. § 1001.952(t)).....	19-17
[G]	Cost-Sharing Waivers by Pharmacies (42 C.F.R. § 1001.952(k)).....	19-17
[H]	Medicare Coverage Gap Discount Program (42 C.F.R. § 1001.952(aa))	19-18
[I]	Other Safe Harbors	19-18
§ 19:2.4	OIG Guidance on Compliance with the AKS	19-19
[A]	Special Fraud Alerts	19-19

	[B]	OIG Compliance Program Guidance	19-20
	[C]	OIG Advisory Opinions	19-21
§ 19:3		Other Anti-Kickback and Related Laws and Industry Codes	19-22
§ 19:3.1		Civil Monetary Penalty for Remuneration to Medicare or Medicaid Beneficiary (42 U.S.C. § 1320a-7a(a)(5), (i)(6))	19-22
§ 19:3.2		Anti-Kickback Act of 1986 (41 U.S.C. §§ 8701–8707).....	19-23
§ 19:3.3		Eliminating Kickback in Recovery Act (18 U.S.C. § 220)	19-23
§ 19:3.4		Stark Anti-Referral Law (42 U.S.C. § 1395mm)	19-24
§ 19:3.5		State Anti-Kickback Laws	19-25
§ 19:3.6		Federal Payment Transparency Reporting Law (Physician Payments Sunshine Act)	19-26
§ 19:3.7		State Gift Prohibitions and Transparency Reporting Laws	19-27
§ 19:3.8		State Compliance Program Requirements	19-28
§ 19:3.9		State Consumer Protection Laws	19-28
§ 19:3.10		State Laws Regulating Professional Conduct of Physicians and Pharmacists	19-29
§ 19:3.11		PhRMA Code.....	19-29
§ 19:3.12		AdvaMed Code	19-30
§ 19:3.13		Health Care Fraud (18 U.S.C. § 1347)	19-32
§ 19:4		Enforcement Risk Areas for Drug and Device Companies Under the AKS.....	19-33
§ 19:4.1		Free Goods, Services, and Other Benefits	19-33
	[A]	Free Goods.....	19-33
	[A][1]	Generally.....	19-33
	[A][2]	OIG Guidance.....	19-33
	[A][3]	Enforcement.....	19-34
	[A][3][a]	Free Product	19-34
	[A][3][b]	Gifts and Travel.....	19-35
	[B]	Reimbursement Assistance and Other Free Services	19-37
	[C]	Patient Assistance Programs	19-38
	[C][1]	OIG Guidance.....	19-38
	[C][2]	Enforcement.....	19-40
	[D]	Coupons	19-42
	[D][1]	Generally.....	19-42
	[D][2]	OIG Position	19-42
	[D][3]	Enforcement.....	19-43
	[E]	Practice Tips	19-44
§ 19:4.2		Bundled Discounts and “Swapping”.....	19-45
	[A]	Generally	19-45

Table of Contents

	[B]	OIG Guidance	19-46
	[C]	Enforcement	19-47
	[D]	Practice Tips	19-48
§ 19:4.3		Consulting Fees	19-48
	[A]	Generally	19-48
	[B]	OIG Guidance	19-48
	[C]	Enforcement	19-49
	[D]	Practice Tips	19-50
§ 19:4.4		Grants	19-51
	[A]	Generally	19-51
	[B]	OIG Guidance	19-52
	[C]	Enforcement	19-52
	[D]	Practice Tips	19-52
	[D][1]	Grants for Research	19-52
	[D][2]	Grants to Support Independent Scientific or Educational Programs	19-53
§ 19:4.5		Post-Marketing Studies and Registries	19-53
	[A]	OIG Guidance	19-53
	[B]	Enforcement	19-54
	[C]	Practice Tips	19-55
	[C][1]	Post-Marketing Studies	19-55
	[C][2]	Registries	19-56
§ 19:4.6		Payments to Pharmacies	19-57
	[A]	Generally	19-57
	[B]	OIG Guidance	19-57
	[C]	Enforcement	19-57
	[D]	Practice Tips	19-58
§ 19:5		Federal False Claims Act (31 U.S.C. §§ 3729–3733).....	19-58
	§ 19:5.1	Generally	19-58
	§ 19:5.2	FCA Prohibitions	19-59
	§ 19:5.3	FCA Liability for Kickbacks.....	19-60
	§ 19:5.4	Liability for Providing Reimbursement Advice	19-61
		[A] Generally	19-61
		[B] OIG Guidance	19-61
		[C] Enforcement	19-61
	§ 19:5.5	Inflation of Reported Drug Prices.....	19-62
	§ 19:5.6	Reporting of Prices to CMS.....	19-63
		[A] Generally	19-63
		[B] OIG Guidance	19-63
		[C] Enforcement	19-64
	§ 19:5.7	Off-Label Promotion As a Basis for FCA Liability	19-64
	§ 19:5.8	Other FDC Act Violations As a Basis for FCA Allegations.....	19-67

Chapter 20 Internal Investigations

Anne K. Walsh & Charles D. Snow

§ 20:1 Overview 20-3

§ 20:2 Triggers of an Investigation..... 20-5

 § 20:2.1 Laying the Foundation 20-5

 § 20:2.2 Sources of Information about Investigable Situations 20-5

 [A] Employees..... 20-5

 [B] Victims 20-6

 [C] Whistleblowers 20-6

 [D] Government Agencies..... 20-6

 [E] Other Third-Party Sources 20-8

 [F] Compliance Hotlines 20-8

 § 20:2.3 Documenting the Complaint 20-9

 § 20:2.4 Public Statements 20-10

§ 20:3 Initiating an Investigation 20-10

 § 20:3.1 Generally 20-10

Table 20-1 Cost/Benefit Analysis of Initiating Formal Versus Informal Internal Investigation 20-12

 § 20:3.2 Timeliness 20-13

 § 20:3.3 Prevention of Retaliatory Claims 20-13

 § 20:3.4 Stopping Ongoing Conduct..... 20-13

§ 20:4 Scope of the Investigation 20-14

 § 20:4.1 Identifying Goals 20-14

 § 20:4.2 Creating a Plan 20-14

§ 20:5 Staffing the Investigation..... 20-15

 § 20:5.1 Generally 20-15

 § 20:5.2 Legal Counsel 20-15

 [A] Generally 20-15

 [B] Internal Versus External Counsel 20-15

 [C] Separate Counsel for Employees and Others..... 20-17

 [D] Privilege Issues 20-19

 § 20:5.3 Investigations by Non-Legal Company Personnel 20-21

 § 20:5.4 Use of Outside Experts 20-21

 § 20:5.5 Oversight of the Investigation..... 20-21

§ 20:6 Conducting the Investigation 20-22

 § 20:6.1 Generally 20-22

 § 20:6.2 Documents 20-23

 [A] Document Preservation 20-23

 [A][1] Custodians 20-23

 [A][2] Information Technology 20-23

 [A][3] Litigation Hold Notices 20-23

Table of Contents

[B]	Document Collection	20-24
[B][1]	Generally.....	20-24
[B][2]	Custodian Interviews	20-24
[B][3]	Paper Documents	20-24
[B][4]	Electronic Files	20-25
[C]	Role of IT Experts	20-25
[D]	Document Management and Review	20-25
§ 20:6.3	Interviews	20-27
[A]	Generally	20-27
[B]	Preparation	20-27
[B][1]	Generally.....	20-27
[B][2]	Selection of Interviewees	20-27
[B][3]	Sequence of Interviews	20-28
[B][4]	Scheduling Interviews	20-29
[B][5]	Interview Outline and Questions	20-29
[B][6]	Providing Documents to Interviewees	20-30
[C]	Conducting Interviews.....	20-30
[C][1]	Interviewers.....	20-30
[C][2]	Tone	20-31
[C][3]	<i>Upjohn</i> Warnings and Other Preliminary Statements	20-31
[C][4]	Asking Questions	20-32
[C][5]	Concluding Instructions.....	20-33
[D]	Interviews of Third Parties.....	20-33
[E]	Other Investigative Techniques.....	20-33
§ 20:7	Investigation Records.....	20-34
§ 20:7.1	Generally	20-34
§ 20:7.2	Document Summaries	20-34
§ 20:7.3	Interview Reports.....	20-34
§ 20:7.4	Reports of Findings	20-35
[A]	Interim Updates	20-35
[B]	Final Report	20-35
§ 20:8	Remedial Actions.....	20-37
§ 20:8.1	Stopping Violative Conduct	20-37
§ 20:8.2	Discipline	20-37
[A]	Generally	20-37
[B]	Verbal Warnings.....	20-37
[C]	Written Warnings.....	20-37
[D]	Training	20-38
[E]	Termination.....	20-38
[F]	Severance Agreements	20-38
§ 20:8.3	Adopting New Policies and Controls.....	20-39
§ 20:8.4	Self-Disclosure.....	20-39
§ 20:9	Special Considerations for International Investigations	20-42

Appendix 20A Internal Investigation and Litigation
 Hold Notice App. 20A-1
 Appendix 20B Sample *Upjohn* Warning..... App. 20B-1

Chapter 21 FDA Inspections

Douglas B. Farquhar, Karla L. Palmer & Mark I. Schwartz

§ 21:1 Role of Inspections 21-2
 § 21:1.1 Overview..... 21-2
 § 21:1.2 COVID-19, the HHS Pandemic Emergency
 Declaration, and Its Effect on FDA Inspections..... 21-4
 § 21:1.3 FDA’s Reasons to Inspect..... 21-5
 § 21:1.4 Potential Outcomes of Inspections..... 21-7
 § 21:2 FDA’s Authority to Access Facilities and Records,
 and Conduct Interviews..... 21-7
 § 21:2.1 Generally 21-7
 § 21:2.2 Authority with Respect to Specific Facilities..... 21-9
 [A] Food and Dietary Supplement Facilities..... 21-9
 [B] Drug and Biologic Facilities 21-10
 [C] Device Facilities..... 21-12
 [D] Cosmetic Facilities..... 21-12
 [E] Foreign Facilities 21-13
 [F] Pharmacies 21-13
 § 21:2.3 Who Conducts an Inspection? 21-14
 § 21:2.4 FDA Credentials and Forms 21-15
 § 21:2.5 Refusal or Delay, the Definition and
 Consequences 21-15
 § 21:2.6 Involvement of State and Local Officials in
 Inspections 21-17
 § 21:3 Preparing for an Inspection..... 21-17
 § 21:3.1 Generally 21-17
 § 21:3.2 Policies..... 21-18
 § 21:3.3 Personnel 21-19
 § 21:3.4 Practice, Practice, Practice..... 21-19
 § 21:4 During an Inspection..... 21-19
 § 21:4.1 Generally 21-19
 § 21:4.2 Questions and Answers 21-21
 § 21:4.3 Keeping a Record..... 21-21
 § 21:4.4 Close-Out Meetings..... 21-21
 § 21:5 Post-Inspection Follow-Up..... 21-22
 § 21:5.1 Form 483 Response..... 21-22
 [A] Generally 21-22
 [B] Timeline 21-23
 [C] How to Address and Format Your Response..... 21-23
 [D] Tips for Success 21-24

Table of Contents

§ 21:5.2 Close Out and the Establishment
Inspection Report..... 21-25

§ 21:5.3 Publicity..... 21-25

§ 21:5.4 Warning Letter Response..... 21-25

 [A] Generally 21-25

 [B] Timeline 21-26

 [C] How to Address and Format Your Response..... 21-26

 [D] Tips for Success 21-27

Chapter 22 Issues Arising from Criminal Cases

James P. Ellison

§ 22:1 Overview 22-2

§ 22:2 How Does a Criminal Investigation Commence? 22-3

 § 22:2.1 Generally 22-3

 § 22:2.2 Agencies That Investigate and Prosecute FDA
 Criminal Matters 22-3

 [A] Criminal Investigators 22-3

 [A][1] FDA Office of Criminal Investigations 22-3

 [A][2] Federal Bureau of Investigation 22-6

 [A][3] U.S. Department of Health and Human
 Services Office of Inspector General 22-7

 [A][4] Others 22-7

 [B] Criminal Prosecutors 22-7

 § 22:2.3 Regulatory Referrals 22-7

 § 22:2.4 Consumer Complaints and Public Health
 Issues 22-8

 § 22:2.5 Whistleblowers, the False Claims Act,
 and *Qui Tams* 22-8

§ 22:3 Parallel Investigations—Government Sharing of
Information 22-9

§ 22:4 Indications That There May Be a Criminal
Investigation 22-9

 § 22:4.1 Generally 22-9

 § 22:4.2 Document Requests 22-10

 [A] Grand Jury Subpoenas 22-10

 [B] HIPAA Subpoenas 22-11

 [C] Other Administrative Subpoenas 22-11

 [D] Privilege Issues, Self-Incrimination, and
 Immunity 22-12

 [D][1] Attorney-Client Privilege 22-12

 [D][2] Attorney Work Product Protection 22-12

 [D][3] Fifth Amendment Privilege Against
 Self-Incrimination 22-14

§ 22:4.3 Testimonial Subpoenas 22-16

 [A] Generally 22-16

 [B] Grand Jury Secrecy 22-16

 [B][1] Generally..... 22-16

 [B][2] Government Obligations..... 22-17

 [B][3] No Obligations on Other Persons..... 22-17

§ 22:4.4 Interviews 22-18

 [A] Generally 22-18

 [B] Represented Parties and Persons 22-19

 [B][1] Current Employees..... 22-19

 [B][2] Former Employees..... 22-20

 [C] Restrictions on the Government..... 22-20

 [D] Ethical Issues for Company Counsel and
 Upjohn Warnings..... 22-21

 [E] Joint Defense Agreements..... 22-23

§ 22:4.5 Search Warrants 22-24

 [A] Generally 22-24

 [B] General Requirements in Issuing and
 Serving a Search Warrant 22-24

 [C] Practical Considerations 22-26

§ 22:5 Influencing the Criminal Investigation..... 22-26

 § 22:5.1 Voluntary Disclosure 22-26

 § 22:5.2 Proffer Sessions and Government
 Presentations 22-27

§ 22:6 Plea Negotiations..... 22-28

 § 22:6.1 Generally 22-28

 § 22:6.2 Sentencing Guidelines—Organizational
 Guidelines 22-28

 [A] Compliance Programs..... 22-28

 § 22:6.3 Non-Prosecution and Deferred Prosecution
 Agreements..... 22-29

 § 22:6.4 Collateral Consequences—Exclusion and
 Debarment..... 22-30

§ 22:7 Select Constitutional Defenses 22-31

 § 22:7.1 First Amendment..... 22-31

 § 22:7.2 Fifth Amendment Due Process
 (Clarity of the Law)..... 22-33

Table of Authorities T-1

Index I-1